Skip to main content
Ab&B Bio-Tech CO., LTD. JS logo

Ab&B Bio-Tech CO., LTD. JS — Investor Relations & Filings

Ticker · 2627 ISIN · CNE1000071P9 HKEX Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2627

About Ab&B Bio-Tech CO., LTD. JS

http://www.abbbio.com

Ab&B Bio-Tech CO., LTD. JS is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of human vaccines and biological preparations that confer active immunity. The company's mission centers on developing globally innovative vaccines and utilizing new technologies to improve traditional vaccines. Its comprehensive pipeline targets infectious diseases and includes candidates across viral, bacterial, conjugate, subunit, and mRNA platforms. The primary commercial product is the Quadrivalent Subunit Influenza Vaccine, approved for individuals aged six months and above. Advanced pipeline assets, such as the 23-valent Pneumococcal Polysaccharide Vaccine and the Freeze-dried Human Rabies Vaccine (Human Diploid Cell), have completed Phase I clinical trials. R&D operations are supported by facilities in Shanghai and Taizhou, with the company emphasizing scientific validation through publications in international journals.

Recent filings

Filing Released Lang Actions
APPOINTMENT OF INDEPENDENT INVESTIGATOR AND INDEPENDENT INTERNAL CONTROL CONSULTANT
Regulatory Filings Classification · 85% confidence The document is an announcement under the Hong Kong Listing Rules about the appointment of external forensic and internal control consultants. It does not provide financial statements or analysis, nor does it constitute an AGM presentation, earnings release, management change, or a formal report. It is a regulatory announcement/compliance notice under listing rules, fitting best into the general Regulatory Filings (RNS) category.
2026-06-05 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2026
Regulatory Filings Classification · 84% confidence The document is a Form FF301“Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed with the Hong Kong Exchange under its Listing Rules. It provides month-end movements in authorised share capital, issued shares and confirmations of public float compliance. This is a routine regulatory compliance filing rather than an earnings or annual report, proxy statement, capital markets transaction, or detailed financial report. It does not announce a report publication nor is it a standalone audit, dividend notice, M&A, or ESG report. It falls under general regulatory/ listing rule filings.
2026-06-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 75% confidence The document is a formal listing of the company’s board composition and committee memberships, detailing the roles and functions of executive, non-executive and independent directors and their committee assignments. It does not present financial data or announce a transaction, dividend, or earnings, nor does it appear to merely publish a report that is attached elsewhere. Instead, it outlines the board structure and governance framework of the company, which aligns with the definition of Governance Information (CGR).
2026-05-27 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 89% confidence The document is the company's Articles of Association outlining corporate governance provisions (general provisions, share issuance, board of directors, senior management, audit, notices, amendments, etc.). It serves as the internal constitution and governance framework rather than a financial report or announcement. This matches the definition of Governance Information (CGR).
2026-05-27 English
(1) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 (2) ABOLITION OF THE SUPERVISORY COMMITTEE, AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RELATED INTERNAL CORPORATE GOVERNANCE POLI
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement by a Hong Kong-listed company detailing the poll results of its Extraordinary General Meeting (EGM), including vote counts for special and ordinary resolutions, and the outcomes of shareholder votes (abolition of the supervisory committee, amendments to articles, director appointments, auditor appointment). This matches the definition of Declaration of Voting Results & Voting Rights Announcements (code DVA).
2026-05-27 English
VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT)
Regulatory Filings Classification · 60% confidence The document is a voluntary announcement by Ab&B Bio-Tech regarding the commencement of Phase I and Phase II clinical trials for a vaccine. It contains no financial data, no management changes, no voting results, no capital transactions, no legal proceedings or M&A activity. It is a corporate update required under listing rules but does not fit any specialized category (e.g., earnings, interim report, board changes). Therefore it defaults to the general regulatory/announcement category: RNS.
2026-05-13 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.